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Abstract 
Intravenous Immunoglobulins (IvIg) are often 
administered to critically ill patients more as an act of 
faith than on the basis of relevant clinical studies. This 
particularly applies to the treatment of sepsis in adult 
patients,  in whom the current guidelines even recommend 
against their use,  despite that many studies demonstrated 
either their beneficial effects in different subsets of 
patients and that some preparations of  IvIg are more 
effective than other. 
The biology of Ig are reviewed, aiming to a more in-depth 
understanding of their properties in order to clarify their 
possible indications in different clinical settings. 
 
1. Introduction 
Intravenous immunoglobulins (IvIg) are currently used in 
multiple pathologic conditions but they are often 
prescribed off-label due the absence of specific guidance 
formulated according to evidence-based medicine (EBM) 
criteria [1]. This particularly applies to patients admitted 
to the intensive care unit (ICU), where IvIg may be used 
either to boost the patients’ immunological capabilities or, 
conversely, to blunt an immune response directed toward 
the patients’ own tissues (for example, in myasthenia 
gravis or Guillan-Barrè syndrome). The uncertainty upon 
their effectiveness in critically ill patients is further 
underscored by the recommendations against the use of 
IvIg reported on the recently issued guidelines of the 
Surviving Sepsis Campaign (SSC) [2].  
The aim of this review is to provide a detailed overview 
about the biological role of  immunoglobulins in 
relationship with their therapeutic use among critically ill 
septic patients admitted to the ICU. 
 
2. Structures and function of immunoglobulins. 
The ultimate mission of the immune system is to 
recognize and destroy extraneous molecules invading the 
host. To be inactivated, a foreign substance must react 
with fixed or circulating receptors, which trigger the final 
response. This task is accomplished by two distinct but 
strictly co-operating systems [3,4]. The innate immune 
system includes the  cells of reticuloendothelial system 
(RES) , the mediators produced and released by these cells 
during the interaction between the hots and the invading 
organism and the complement cascade. The number of 
receptors present on the surface of innate immune system 
cells is genetically determined and, albeit numerically 
relevant, cannot match the huge variability of microbial 
antigenic epitopes. Thus, a more flexible system is 
required in order to face the myriad of agents and/or 
substances that come into contact with the host. This 
second mechanism, known as adaptive immunity due to 
its capability to cope with continuously changing antigens, 
involves Ig, which are encoded by genes that are able to 
undergo somatic recombination and hypermutation. Ig are 
secreted by plasma cells, which are derived from B 
lymphocytes that are activated by trapping antigens on a 
cell-surface receptor and stimulation with CD4+ T 
lymphocytes. Antibodies belong to five different classes 









The IgG class is considered the prototypical structure, and 
consists of a Y-shaped molecule comprised of two 
identical heavy (H) and light (L) peptide chains. Both H 
and L chains are divided into a variable (V) domain that 
reacts with the antigen, and a constant (C) region that 
activates the various components of the innate immune 
system, triggering a response (for example, phagocytosis, 
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antibody-mediated and cell-mediated cytotoxicity, and 
complement-mediated lysis) (Figure 2). The V regions 
contains three hypervariable regions which are the 
ultimate responsible of the specific of each molecule of Ig. 
The H and L regions are linked together by electrostatic 
forces in association with disulphuric bridges. 
 
Figure 2. Schematic two-dimensional structure of an IgG 
molecule. VH and VL indicate the variable regions of the 
heavy and light chains, respectively. The different 
epitopes are recognized by the variable regions located on 
both the light and heavy chains (Fab region). The CDR 
segments are hypervariable domains located in the Fab 
regions, which are separated from each other by relatively 
constant polypeptide chains. The Fc region binds to 
complement and to the receptors located on the surface of 
the RES cells and triggers their activation. Legend: CDR: 
complementary determining region (hypervariable 
regions); COOH: carboxylic terminal region; C: constant; 
Fab: fragment antigen binding; Fc: fragment crystallizable 
region; H: heavy; IgG: immunoglobulin G; L: light; NH2: 
aminic terminal region;; V: variable. 
 
The region connecting the two functional parts can 
undergo conformational changes in order to re-shape the 
molecule according to the antigen variability.  
 
Therefore, Ig can be considered biochemical transducers 
able to exert many different actions (Table 1) 
 
Toxin inactivation 
Neutralization of endotoxin and exotoxins 
Increase clearance of endotoxin 
Reduce bacterial cell adherence, invasion, and migration 
Stimulation of the leukocyte and serum bactericidal 
action 
Enhancement of endotoxin-induced neutrophil oxidative 
burst (7S-IvIgG); intact  
Reduction of endotoxin-induced neutrophil oxidative burst 
(5S-IvIgG; F(ab')2 fragments and IgM) 
Enhancement of serum opsonic activity 
Modulation of cytokine effect 
Modulation of the release of cytokine and their 
antagonists 
 Pro-inflammatory mediators 
 Anti-inflammatory mediators 
Infusion of cytokines and antagonists contained in the Ig 
preparations 
Cytokine neutralization by anti-cytokine antibodies 
Modulation of the complement cascade 
Table 1. Possible mechanisms of action of 
immunoglobulins  
 
Although these actions can justify the administration of 
IvIg in circumstances characterized by the depression of 
the immunitary capabilities, yet they are widely used in 
other disease determined by the production of 
autoantibodies directed against the patients’s own tissues, 
such as the myasthenia gravis, the Gullan-Barrè syndrome 
etc. These opposing indications are a result of the 
pleiotropic effects exerted by the Ig on the immune 
system, which include either the augmentation of the 
immune response through the above described 
mechanisms but  also the down regulation of the 
inflammatory response via the reduced production of 
tumor necrosis factor- (TNF-) and other inflammatory 
mediators  and the increased release of soluble receptors 
for a number of cytokines [5-7]. This dual IvIg-mediated 
effects on the inflammatory response suggest that they 
may be suitable for the treatment of sepsis, which can be 
characterized initially by an excessive production of 
inflammatory mediators which can be followed in a later 
stage by the overall reduction of the immune response [8-
9], ultimately leading to an immunoparalysis. Besides the 
well recognized circumstances associated with the down-
regulations of the immunitary response, including the 
AIDS, the administration of immunosuppressant agents 
etc, this hypo responsive state characterizes the ICU 
clinical course of frail patients with multiple underlying 
pathological conditions, who often survive the initial 
insult (e.g. pneumonia, emergency surgical interventions 
etc) but fail to recovery and succumb many weeks after 
the admission.  
An increasing number of mediators are involved in this 
two-step process which  are linked by a complicated array 
of positive and negative feedback loops [8-10].  
Despite the recommendations of the SCC, a number of 
investigations demonstrated that (a) the administration of 
IvIg are associated with the reduction of the mortality of 
patients with sepsis and sepsis-related conditions  [11-
14],; and (b) IvIg preparations containing IgM and IgA are 
more effective than those containing IgG alone [15-18]. 
 
3. The Case of IgM 
As stated above, patients given IvIg containing elevated 
concentrations of IgM have an improved survival as 
compared with the control and those treated with IgG 
independently from the age, the underlying conditions and 
the infecting germ. Although the effect can be ascribed to 
multiple factors, including the timing of administration 
and the correctness of the other therapeutic actions, it is 
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hypothesizable that IgM supplementation per se  can play 
some role in the improved survival, as it has been 
demonstrated that plasma values of IgM are reduced in 
severe sepsis and septic shock and this reduction appears 
to be more marked and persisting in nonsurvivors  [19,20]. 
Then, on the basis of these observations, it is worthwhile 
to describe with more details the biological properties of 
IgM. 
IgM is the first antibody produce during an infection, 
appears first during ontogenesis and has been found 
throughout all classes of vertebrates  [21]. It can exist in a 
dimeric form on the surface of the membrane of the B 
cells and circulates as a  pentamer  (occasionally as a 
hexamer) in the blood. Its unique structure allows IgM 
molecules to form strong interactions with different 
ligands, and has a an extremely higher affinity for the 
complement than IgG. Experimentally, IgM allows the 
clearance of apoptotic cells in the immunitary cells in the 
peritoneal macrophages, and the process requires the 
activation of Complement. Although it is not yet clear 
which subset of B cells account for its production, it 
appears that both B1 and B3 B cells are extensively 
involved [21]. The role played by IgM during bacterial, 
viral and fungal infections has been enlightened by studies 
performed in IgM- deficient mice. On the basis of these 
observations, it is likely that the  circulating pentameric 
IgM molecules bind ligands more avidly than those 
present on the cell surface; it is not known if, in the 
presence of reduced blood IgM concentrations, their role 
could be replaced by these latter [21]. Surprisingly 
enough, less it is know about the kinetics as well as the 
precise therapeutic role IgM in humans. Besides the above 
quoted investigations which demonstrated that IgM 
concentrations are decreased in septic shock patients and 
particularly in those with a poor prognosis [19,20], it 
appears that reduced levels of this molecule in association 
with diminished number of natural killer cells (< 58 mg/dl 
and 140 cell/ml, respectively) are associated with an 
increased risk of death also in non-septic critically ill 
patients. Should this findings be confirmed in other 
studies, the supplementation of IgM could be indicated in 
life-threatening conditions other than sepsis [22].  
 
4. Conclusions 
Currently, the administration of IvIg represent the easiest, 
fastest  and less harmful way to interfere with the 
immunitary system of critically ill patients. Due to their 
multiple effects, IvIg can be used to boost the  response to 
an infection, to down-regulate an excessive inflammatory 
response and to abate an autoimmunitary process. The 
basic knowledge of the biology of Ig is warranted to better 
individuate the pathophysiologic conditions in whom their 
use is most valuable. Moving from the lab to the clinical 
arena, future clinical studies should be addressed toward 
some relatively unknown aspects of preparations 
containing IgM, including their T/2, the dose-response 
curve and their interaction with the antibiotics. 
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